Disease · HP_0002098
Respiratory distress
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Respiratory distress. Diseases, record HP_0002098. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002098
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Respiratory distress
- Open Targets ID
- HP_0002098
- Other names
- Breathing difficulties, Labored breathing, Laboured breathing
- Highest stage of its drugs
- Phase 3, for 5 of its 18 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs18
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LIDOCAINE | CHEMBL79 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MAGNESIUM SULFATE | CHEMBL3989857 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NESIRITIDE | CHEMBL1201668 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PIRFENIDONE | CHEMBL1256391 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| UPADACITINIB | CHEMBL3622821 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CAFFEINE CITRATE | CHEMBL1200569 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ANAKINRA | CHEMBL1201570 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ASPARTYL-ALANYL-DIKETOPIPERAZINE | CHEMBL4297349 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BRILACIDIN | CHEMBL2219413 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 18
See all 18 drugsTargets43
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADORA1 | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/134 | Drugs and targets |
| ADORA2A | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/136 | Drugs and targets |
| ADORA3 | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/140 | Drugs and targets |
| BTK | Tyrosine-protein kinase BTK | 1 | Tyrosine-protein kinase BTK inhibitor | Phase 2 | https://conductscience.org/library/genes/695 | Drugs and targets |
| CD80 | T-lymphocyte activation antigen CD80 | 1 | T-lymphocyte activation antigen CD80 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/941 | Drugs and targets |
| CD86 | T-lymphocyte activation antigen CD86 | 1 | T-lymphocyte activation antigen CD86 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/942 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel allosteric antagonist | Unknown | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel allosteric antagonist | Unknown | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel allosteric antagonist | Unknown | https://conductscience.org/library/genes/2556 | Drugs and targets |
1 to 10 of 43
See all 43 targetsTrials16
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00475852 | A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure | Phase 3 | 7,141 | 2012-05-10 | Heart Decompensation | NESIRITIDE | Its record names the disease | ClinicalTrials.gov |
| NCT04868890 | A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19 | Phase 2 | 200 | 2022-12-07 | Covid19 | ASPARTYL-ALANYL-DIKETOPIPERAZINE | Its record names the disease | ClinicalTrials.gov |
| NCT04784897 | A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19 | Phase 2 | 120 | 2022-09-16 | COVID-19 | BRILACIDIN | Its record names the disease | ClinicalTrials.gov |
| NCT04382586 | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants | Phase 2 | 63 | 2022-03-02 | COVID-19 Pulmonary Complications, COVID-19 | ZANUBRUTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT06928272 | Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | Phase 3 | 348 | Long COVID | PIRFENIDONE, UPADACITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT03239327 | Vaginal Misoprostol to Improve the Neonatal Respiratory Outcome | Not applicable | 292 | Neonatal Respiratory Distress | MISOPROSTOL | Its record names the disease | ClinicalTrials.gov | |
| NCT06785272 | Magnesium Trial in Acute Asthma in Emergency Department | Phase 3 | 192 | Asthma | MAGNESIUM SULFATE | Its record names the disease | ClinicalTrials.gov | |
| NCT06026163 | Caffeine as an Adjuvant Therapy for Late Preterm Infants With Respiratory Distress | Phase 2/3 | 134 | Prematurity, Respiratory Disease, Ventilator Lung; Newborn | CAFFEINE CITRATE | Its record names the disease | ClinicalTrials.gov | |
| NCT04412291 | A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study | Phase 2 | 120 | Covid-19 | ANAKINRA, TOCILIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06563063 | Finding ED90 of Flumazenil for Selective Improvement of Respiratory Distress by Remimazolam | Not applicable | 60 | Stomach Neoplasm | FLUMAZENIL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 16
See all 16 trialsComparisons in its trials17
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Nesiritide vs Placebo: Number of Patients With Renal Impairment | 1,032 of 3,498 | 968 of 3,509 | 7,007 | NCT00475852 | Trial comparisons |
| Nesiritide vs Placebo: All-Cause Mortality Through Day 30 | 126 of 3,498 | 141 of 3,509 | 7,007 | NCT00475852 | Trial comparisons |
| Nesiritide vs Placebo: All-Cause Mortality Through Day 180 | 429 of 3,498 | 447 of 3,509 | 7,007 | NCT00475852 | Trial comparisons |
| Nesiritide vs Placebo: serious adverse events | 5 of 3,498 | 2 of 3,509 | 7,007 | NCT00475852 | Trial comparisons |
| Nesiritide vs Placebo: Composite of Persistent or Worsening Heart Failure and All-Cause Mortality | 147 of 3,459 | 165 of 3,462 | 6,921 | NCT00475852 | Trial comparisons |
| Nesiritide vs Placebo: Composite of Cardiovascular Rehospitalization and Cardiovascular Mortality | 372 of 3,423 | 402 of 3,415 | 6,838 | NCT00475852 | Trial comparisons |
| Nesiritide vs Placebo: Composite of Rehospitalization Due to Heart Failure and All-Cause Mortality | 321 of 3,423 | 345 of 3,413 | 6,836 | NCT00475852 | Trial comparisons |
| Active vs Control: deaths from any cause | 2 of 64 | 1 of 65 | 129 | NCT04868890 | Trial comparisons |
| Active vs Control: serious adverse events | 2 of 64 | 4 of 65 | 129 | NCT04868890 | Trial comparisons |
| Zanubrutinib + Supportive Care vs Placebo + Supportive Care: Number of Participants With Respiratory Failure-free Survival | 27 of 30 | 28 of 33 | 63 | NCT04382586 | Trial comparisons |
1 to 10 of 17
See all 17 comparisons in its trialsPapers from its trials23
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 39906744 | DERIVED | 1 | PubMed |
| 38157348 | DERIVED | 1 | PubMed |
| 37725680 | DERIVED | 1 | PubMed |
| 36314126 | DERIVED | 1 | PubMed |
| 33775110 | DERIVED | 1 | PubMed |
| 31606362 | DERIVED | 1 | PubMed |
| 30354576 | DERIVED | 1 | PubMed |
| 29781109 | DERIVED | 1 | PubMed |
| 29431103 | DERIVED | 1 | PubMed |
| 28641792 | DERIVED | 1 | PubMed |
1 to 10 of 23
See all 23 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0002098
GET https://conductscience.org/api/diseases/v1/HP_0002098/targets?page=2